Despite the company’s inconsistent communication and the ongoing FREP proceedings, the high impairment was fully reversed which sent positive shockwaves through the P&L and the balance sheet compared to a year ago. Based on the positive price developments, management lifted its guidance once again and indicated a strong 2022, excluding the REKs-related one-off. Q3 figures were a notch weaker than expected, the same was true for consensus.